What Is Atypical Lobular Hyperplasia and Cancer Risk?

Atypical lobular hyperplasia (ALH) is a non-cancerous breast finding in which the cells lining the milk-producing lobules have multiplied and taken on an unusual appearance, but not enough to qualify as carcinoma in situ. It raises a woman’s risk of eventually developing breast cancer to roughly four to five times that of the general population, which translates to about a one-in-ten chance over five years and closer to one in six or seven over a decade. ALH is not cancer itself, but it occupies an uncomfortable middle ground that reshapes how screening, prevention, and follow-up should look for anyone who receives the diagnosis.

How ALH Is Found

Most women who learn they have ALH never felt a lump or had any breast symptom. The finding almost always surfaces incidentally during a core needle biopsy performed for something else, often calcifications flagged on a mammogram or an area of enhancement on MRI. In one study of cases where lobular neoplasia (the umbrella term covering both ALH and its more advanced relative, lobular carcinoma in situ) was the highest-risk lesion, about 72 percent of those with a visible imaging correlate had presented as calcifications on mammography, with the remainder picked up on MRI as a focus or non-mass enhancement.¹ In a separate series focused on MRI-guided biopsies, every single lobular neoplasia finding was invisible on both mammography and ultrasound, meaning MRI was the only modality that detected it.²

Because ALH has no reliable imaging signature of its own, it is essentially a pathologist’s diagnosis. You go in for a biopsy targeting something else, and the tissue comes back with this additional finding. That “accidental discovery” quality is one reason the diagnosis can feel disorienting: there was no warning, no symptom, and now there is a new risk category attached to your chart.

What the Numbers Actually Say About Future Cancer Risk

The headline figure is a roughly four- to five-fold increase in relative risk compared to women without the finding. A large review from the New England Journal of Medicine put the risk at approximately four to five times that of the general population and noted that about 29 percent of women with any atypical hyperplasia developed breast cancer within 25 years of their biopsy.³ A 2024 systematic review and meta-analysis estimated that about one in ten women with ALH will develop breast cancer within five years of diagnosis, rising to roughly 15 percent at ten years.⁴

Those numbers, while real, also mean the majority of women with ALH will not develop cancer. Roughly 70 to 80 percent never do, even over long follow-up. That is a critical point to hold onto when processing the diagnosis, because the risk conversation can easily tip toward alarm when the four-to-five-fold multiplier is quoted without its denominator.

Family history compounds the picture. Women who had atypical hyperplasia and two or more first-degree relatives with breast cancer carried a cumulative incidence of roughly 40 percent at 25 years.³ So the same diagnosis can mean very different things depending on the rest of your personal risk profile.

Not Just a General Risk Marker

For years, ALH was thought of mainly as a flag that both breasts were at higher risk. That framing has shifted. A large retrospective study published in The Lancet found that invasive cancer after an ALH diagnosis was about three times more likely to develop in the same breast where the ALH was found than in the opposite one.⁵ Among women whose ALH was the sole atypical finding, the ipsilateral-to-contralateral ratio was roughly 17 to 5. A longitudinal cohort study from the Mayo Clinic confirmed a similar roughly two-to-one ratio of same-breast to opposite-breast cancers for both ALH and atypical ductal hyperplasia, and noted that cancers developing within the first five years after biopsy were especially likely to occur in the ipsilateral breast (about 80 percent of early cancers).⁶

This matters because it suggests ALH is not purely a passive bystander indicating generalized breast vulnerability. It behaves at least partly as a local precursor, something closer to a step on the road to cancer in that specific area of tissue. The researchers who published the Lancet cohort described it as “intermediate between a local precursor and a generalised risk for both breasts,” and that hybrid model fits the data better than either extreme.⁵ As years go by after the biopsy, the risk becomes more evenly distributed between breasts, which is consistent with the idea that the earliest cancers are more directly seeded by the ALH itself, while later cancers reflect the broader field of risk.

What Happens at the Molecular Level

The signature molecular change in ALH is the loss of a protein called E-cadherin, which normally acts as a kind of glue holding breast cells together at their surfaces. In a study evaluating ALH and lobular carcinoma in situ (LCIS) lesions, nearly all showed absent E-cadherin and its partner proteins beta-catenin and alpha-catenin on immunohistochemistry.⁷ The interesting twist was that LCIS samples had actual mutations in the gene encoding E-cadherin, but ALH samples did not. The protein was absent without the gene being broken in the conventional sense. The researchers concluded that some other silencing mechanism was shutting down the E-cadherin adhesion complex early on, even before mutations accumulated.

A follow-up line of research identified that mechanism: epigenetic silencing through methylation of the CDH1 gene promoter. In one study, 13 out of 13 ALH or LCIS samples showed this methylation, and it appeared to be the first of two “hits” needed to permanently disable E-cadherin and allow lobular cancer to develop.⁸ In plain terms, the gene gets chemically muzzled before it gets mutated. That is why ALH already looks and behaves like a lobular process under the microscope even though it has not yet acquired the DNA damage seen in full-blown LCIS or invasive lobular carcinoma. It is also why researchers view ALH and LCIS as points on a single biological continuum rather than unrelated diagnoses.

Should ALH Be Surgically Removed?

When ALH shows up on a core needle biopsy, the traditional next step was to recommend surgical excision of the area to make sure nothing more worrisome was hiding nearby. The concern is the “upgrade” rate, meaning how often the excision specimen reveals cancer or a higher-risk lesion that the needle biopsy missed. For isolated ALH found on needle biopsy, the upgrade rate is low. A study of 87 such cases found that only three (about 3.4 percent) were upgraded at excision, and all three upgraded to ductal carcinoma in situ rather than invasive cancer.⁹ The upgrade rate was somewhat higher (about 8 percent) in women who already had a concurrent breast cancer diagnosis elsewhere.

Because the upgrade rate is consistently low when ALH is truly isolated and the imaging is concordant with a benign finding, guidelines have eased. A review in the American Journal of Roentgenology concluded that in specific circumstances, ALH and LCIS can safely be managed with imaging surveillance rather than surgical excision.¹⁰ In practice, the decision depends on whether the biopsy adequately sampled the area, whether there is imaging-pathology concordance, and whether the patient has additional risk factors. The shift away from automatic excision is relatively recent and not universal. Some institutions still default to surgery, so the recommendation you receive can depend on where you are being treated.

What Later Cancers Look Like

If cancer does eventually develop after an ALH diagnosis, it tends to have a particular profile. In one series tracking women who developed invasive breast cancer after a prior core biopsy showing atypical hyperplasia, about three-quarters of the invasive cancers were small (pathologic T1, meaning 2 centimeters or less), and the vast majority were estrogen receptor-positive.¹¹ A larger study from the Mayo Clinic examining cancers that arose in women with prior benign breast disease found that those with atypical hyperplasia had a particularly high frequency of estrogen receptor-positive cancers, at 91 percent.¹²

The predominance of estrogen receptor-positive tumors is not just a pathological footnote. It directly influences treatment, since these cancers respond to hormonal therapies. And it makes the risk-reduction strategies discussed below especially relevant, because the same hormonal pathways that drive these tumors are the ones that chemoprevention drugs target.

Medications That Lower the Risk

Risk-reducing medication, sometimes called chemoprevention, is one of the most effective tools available for women with ALH, and it is underused. Tamoxifen has the longest track record. The largest prevention trial found that women with a history of atypical hyperplasia who took tamoxifen for five years had an 86 percent relative reduction in invasive cancer. A follow-up trial showed that the protective effect persisted 10 to 20 years after stopping the drug. For women concerned about tamoxifen’s side effects, a low-dose regimen (5 mg per day, a quarter of the standard dose) was reported to cut breast cancer risk by about half in women with ALH, LCIS, or ductal carcinoma in situ over a three-year course.¹³

Aromatase inhibitors are an alternative for postmenopausal women. Exemestane showed a 65 percent reduction in invasive breast cancer compared with placebo, and anastrozole taken for five years was associated with a roughly 53 percent decrease in breast cancer that persisted long term, with about a 36 percent reduction still evident at 12 years.¹³ A separate analysis confirmed that chemoprevention significantly reduced breast cancer risk across all atypia types, including ALH specifically.¹⁴

Despite these numbers, uptake remains low. Many women are never counseled about the option, and those who are often worry about side effects like hot flashes, joint pain, or the small risk of blood clots with tamoxifen. A conversation about the tradeoffs is worth having, especially for women whose family history pushes their cumulative risk into higher territory.

Surveillance After an ALH Diagnosis

An ALH diagnosis changes your screening schedule. The American College of Radiology recommends that women with atypia or LCIS consider supplemental surveillance with breast MRI, especially when other risk factors are present.¹⁵ In practice, this often means annual mammography alternating with annual MRI at six-month intervals, so you are getting some form of imaging every six months. The rationale is that mammography alone misses some lesions in women with dense breasts or lobular-type changes, and MRI picks up enhancement patterns that mammography cannot.

How long this intensified surveillance should last is an open question. Risk does not vanish after five or ten years. The steady upward slope of cumulative risk over 25 years seen in cohort studies means that relaxing surveillance after a certain interval is not straightforwardly justified. Most guidelines recommend continuing enhanced screening indefinitely, or at least until the woman’s life expectancy or overall health status makes the screening unlikely to yield benefit.

Why Risk Calculators Struggle with ALH

You might assume that standard breast cancer risk calculators could tell you precisely how worried to be, but they perform surprisingly poorly in women with atypical hyperplasia. A study testing the Tyrer-Cuzick model, one of the most widely used tools, found that it overpredicted invasive breast cancer by nearly double in the first ten years after biopsy. The observed-to-predicted ratio was about 0.53, meaning only about half the expected cancers actually materialized.¹⁶ On top of that, the model could not meaningfully distinguish individual women who would develop cancer from those who would not. A systematic review of risk assessment tools confirmed that both the Gail and Tyrer-Cuzick models had poor discriminatory ability in this population.¹⁷

The practical implication is that when your doctor runs one of these calculators to determine whether you qualify for enhanced screening or chemoprevention, the number it produces should be taken as a rough guide rather than a precise prediction. The models were built on general populations and do not handle atypia well. If you have ALH, your risk is elevated regardless of what the calculator outputs, and management decisions should reflect that.

Lifestyle Factors and Hormones

A reasonable question after an ALH diagnosis is whether everyday choices or medications you are already taking change your risk further. A study of women biopsied for benign breast disease found that use of hormone replacement therapy was associated with a substantially higher risk of subsequent breast cancer, while being postmenopausal (without HRT) was actually associated with reduced risk compared to premenopausal women.¹⁸ The same study confirmed that having atypical hyperplasia itself was a strong independent risk factor.

As for exogenous estrogen in forms like vaginal estrogen, oral contraceptives, or other hormonal birth control, a study specifically evaluating women with lobular neoplasia found no statistically significant difference in any of these exposures between women who went on to develop cancer and those who did not.¹⁹ That study was small enough that a real effect could have been missed, so the absence of a finding is not the same as proof of safety. But it does suggest that the relationship between exogenous estrogen and cancer progression in women with ALH is not straightforward, and decisions about hormonal medications should involve weighing the specific type of exposure, the dose, and the rest of the risk picture with your clinician.

Racial Differences in Risk After ALH

Research on whether race or ethnicity changes the picture after an ALH diagnosis is still developing, and the findings so far are more nuanced than “the risk is the same for everyone.” One study examining whether atypia type, upgrade risk, and long-term cancer outcomes varied by race or ethnicity found no significant differences.²⁰ But a study from the Siteman Cancer Center painted a more complex picture: Black women with atypical hyperplasia who were premenopausal had a markedly higher hazard of subsequent breast cancer compared to White women with the same diagnosis. The difference was particularly pronounced in the first four years after biopsy.²¹

A meta-analysis that pooled data across racial groups confirmed elevated risk from atypical hyperplasia in both Asian and Black women, though the confidence intervals were wide given the small number of studies.²² This is an area where the evidence is thin because most of the foundational atypia research was done in predominantly White cohorts. The takeaway for now is that ALH raises risk across racial groups, but the degree and timing of that risk may not be identical, and premenopausal Black women with the diagnosis deserve particularly close follow-up.

How ALH Differs from Its Close Relatives

ALH sits on a spectrum of lobular neoplasia alongside LCIS. The difference between the two is largely one of extent: ALH involves fewer than half of the acini (the small round structures within a lobule), while LCIS fills and distends more than half of them. The biological underpinnings are shared, including E-cadherin loss, and the distinction is based on how much of the lobule is involved rather than a fundamentally different process. Both carry increased risk, but LCIS is generally associated with a somewhat higher magnitude. In the 2024 meta-analysis, five-year cancer incidence was about 9.3 percent for LCIS versus about 9.7 percent for ALH, though these confidence intervals overlapped substantially and the ten-year figures were similarly close.⁴

Atypical ductal hyperplasia (ADH) is a different entity that arises in the ducts rather than the lobules and retains E-cadherin expression. It carries a broadly similar risk multiplier but leads more often to ductal rather than lobular cancers. Flat epithelial atypia (FEA) occupies the lower end of the risk spectrum, with about half the five-year incidence of ALH or LCIS. These distinctions matter mainly for treatment planning and the type of surveillance recommended, since the management approach for each lesion has evolved differently. For ADH, surgical excision after a core biopsy diagnosis is still broadly recommended, while for ALH the trend has moved toward observation in selected cases, as described above.

One older study added a finer-grained look at risk within ALH itself. When ALH cells also extended into the surrounding duct system (a pattern called “ductal involvement by cells of atypical lobular hyperplasia”), the relative risk climbed to about 6.8 times that of the general population, approaching LCIS territory. Without that ductal extension, the risk dropped to about 2.7 times.²³ This is a detail most patients will never hear about, but it underscores that even within a single diagnosis, the biology is not uniform, and pathology details can meaningfully refine risk estimates for those who dig into their reports.